Immunotherapy and endothelin receptor antagonists for treatment of castration-resistant prostate cancer
出版年份 2013 全文链接
标题
Immunotherapy and endothelin receptor antagonists for treatment of castration-resistant prostate cancer
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF CANCER
Volume 133, Issue 7, Pages 1743-1750
出版商
Wiley
发表日期
2013-03-18
DOI
10.1002/ijc.28162
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone
- (2012) Joel B. Nelson et al. CANCER
- Epidemiology of castration resistant prostate cancer: A longitudinal analysis using a UK primary care database
- (2012) C.J. Hirst et al. Cancer Epidemiology
- Randomized Trial of Autologous Cellular Immunotherapy with Sipuleucel-T in Androgen-Dependent Prostate Cancer
- (2011) T. M. Beer et al. CLINICAL CANCER RESEARCH
- Current and Emerging Treatment Options for Castration-Resistant Prostate Cancer: A Focus on Immunotherapy
- (2011) Winald R. Gerritsen et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer
- (2011) F. Dayyani et al. JNCI-Journal of the National Cancer Institute
- New Therapeutic Strategies for Castration-Resistant Prostate Cancer
- (2011) Tomoaki Tanaka et al. Recent Patents on Anti-Cancer Drug Discovery
- Horizon scanning for novel therapeutics for the treatment of prostate cancer
- (2010) D. Bianchini et al. ANNALS OF ONCOLOGY
- Docetaxel-based combination therapy for castration-resistant prostate cancer
- (2010) M. D. Galsky et al. ANNALS OF ONCOLOGY
- Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind,
- (2010) Nicholas D. James et al. BJU INTERNATIONAL
- Recent Advances in Understanding Hormonal Therapy Resistant Prostate Cancer
- (2010) K.V. Donkena et al. CURRENT CANCER DRUG TARGETS
- Estimates of cancer incidence and mortality in Europe in 2008
- (2010) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- A Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated Extensive-Stage Small Cell Lung Cancer
- (2010) Jingwei Jiang et al. Journal of Thoracic Oncology
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054
- (2009) James W. Growcott ANTI-CANCER DRUGS
- Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
- (2009) Celestia S. Higano et al. CANCER
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
- (2009) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
- (2009) William P Harris et al. Nature clinical practice. Urology
- Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer
- (2008) Joel B. Nelson et al. CANCER
- ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer
- (2008) Ruth Warren et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started